Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Therapeutics LLC

Latest From Orphan Therapeutics LLC

Mallinckrodt pays $2.3bn for Ikaria

In signing a deal to acquire neonatal critical care specialist Ikaria, Mallinckrodt is expecting to see immediate gains in both its top and bottom line for fiscal 2015. The $2.3bn deal brings it a nitric vasodilator and accompanying device for newborns with a respiratory failure, and North American rights to a candidate to treat a rare life-threatening condition, hepato-renal syndrome.

Neurology Japan

Ikaria’s Hybrid Business Model Taps Big Pharma Trends

Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.

BioPharmaceutical Strategy

Australian Lucassin approval as US trial continues

Australian regulators have approved Ikaria's Lucassin (terlipressin) for the treatment of hepatorenal syndrome type 1 (HRS 1) in patients who are actively being considered for a liver transplant, making it the first approved treatment for HRS 1, the company said.


Ikaria plans $200 million IPO

Ikaria, a US-based biotherapeutic company, is hoping to raise $200 million through an IPO. It intends to list on Nasdaq.

Cardiovascular Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Orphan Therapeutics LLC
  • Senior Management
  • Peter Teuber, PhD, Pres.
  • Contact Info
  • Orphan Therapeutics LLC
    Phone: (908) 849-4805
    3 Werner Way
    Ste. 210
    Lebanon, NJ 08833